A Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral MK-8591 Once-Monthly in Participants at Low- Risk for HIV-1 Infection
Latest Information Update: 14 Apr 2023
Price :
$35 *
At a glance
- Drugs Islatravir (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme Corp.
- 10 Apr 2023 Status changed from active, no longer recruiting to completed.
- 21 Feb 2023 Planned End Date changed from 28 Feb 2023 to 30 Mar 2023.
- 17 Jan 2023 Planned End Date changed from 30 Mar 2023 to 28 Feb 2023.